They are narrowly targeting very specific genetic mutations in orphan indications for which they are certain about achieving maximum efficacy with their TLR Antagonist platform. This strategy maximizes successful trial results and shortens time to market. It's seems to be a very deliberate strategy, and one that apparently Baker Bros likes.
I'd also bet they will partner IMO-8400 for the Psoriasis indication shortly after the Phase 2 results are announced. That's another quick way to bring in lots of cash to further implement their long term strategy.
Consolidation today, shares get loaded ahead of tomorrow's presentation. Upgrade as soon as Wednesday. Friday we close at a new 52 week high. It's the way the game is played.
Offering is now behind us.
That begins today.
When you purchase shares of a company, it's assets are part of it. Also good DD always includes checking out the entire story. Based on the G street view, they either operate out of an Arcade or the clothing store across the street. Your comfortable investing your money in that?
It's greyed out on yahoo finance. And there's no listing on Nasdaq. PRAN is an ADR, so presumably you'd need to check their ASX exchange. But there they only show "Announcements". There are a lot of Appendix 3B's filed which talk about options, but I can't tell if those are option grants or exercises by company employees, or something else. There's got to be a list of transactions somewhere to review?
Can anyone provide a pointer? It's not listed anywhere on Nasdaq since this thing trades in AUS. I'd like to see if the insiders are dumping shares into this pump. Thanks.
9 Person company, with no products on the market, or revenue, located somewhere in Australia. 2 Trials running with less than 170 patients, and no major institutional ownership to speak of. And it has a market cap over 500 Million? Seriously? Tell me why I should by it at these levels?
RSV, and why it won't help NVAX. What most people don't realize is that you can be reinfected with RSV over and over again. A single vaccine given to the mother cannot confer immunity to the child forever. Can anyone point to literature that says otherwise? RSV is one of those viruses that kids get each year, sometimes a couple times during the season. Any news on RSV from NVAX will IMO, promptly cause a sell off. I think you saw some of that yesterday.
Can't argue with my point though. No serious institutions are touching Prana. Makes you wonder why....
Where's Orbimed, Baker Bros, FMR, etc? Did they actually miss this Biotech, or do they know something all the retail investors don't? Something isn't right here. Think about it.